Daiichi Sankyo's Prasugrel Shows Reduction Of Recurrent Cardiovascular Events
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo announced August 22 that a Phase III study showed patients who took prasugrel for acute coronary syndromes were less likely to have a recurrent event than those who took competing Sanofi-Aventis drug clopidogrel. The study was conducted on patients who had a previous cardiovascular or cerebral event. Recurrent rate for prasugrel was 10.8 compared to clopidogrel's 15.4 percent. Daiichi Sankyo and Eli Lilly are jointly applying for approval. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.